# Infusion Pharmacy & Home Infusion M&A in 2026: Valuations, Buyers, and What PE Is Paying > Home infusion and specialty infusion pharmacy M&A activity has accelerated meaningfully in 2026. Here is what owners of home infusion, ambulatory infusion, and specialty pharmacy platforms should know about valuations, active buyers, and deal mechanics. Source: https://www.hendonpartners.com/insights/infusion-pharmacy-home-infusion-ma-2026 Author: Neli Gertner Published: 2026-05-05 Category: Industry Verticals Tags: infusion, home-infusion, specialty-pharmacy, M&A, valuation, 2026 ---Home infusion and specialty infusion pharmacy M&A activity has accelerated meaningfully through 2025 and 2026. Three structural forces — the expanding biologic and specialty drug pipeline, payer preference for lower-cost site-of-care settings, and PE platforms in scale-up mode — have created sustained demand for home infusion, ambulatory infusion, and specialty pharmacy businesses across the country. For owners of home infusion, ambulatory infusion suite (AIS), and specialty pharmacy platforms, 2026 represents one of the most favorable exit windows of the cycle. This guide covers what sellers should know. --- ## Why Infusion M&A Is Active in 2026 **1. Biologic and specialty drug expansion.** The pipeline of injectable and infused biologics, specialty drugs, and rare-disease therapies continues to grow. A meaningful share of these therapies will be administered at home or in AIS settings rather than hospitals. **2. Payer site-of-care steerage.** Commercial payers and Medicare Advantage plans actively steer patients away from hospital outpatient infusion to lower-cost home and AIS settings. This payer preference creates structural demand growth for the home infusion segment. **3. PE consolidation cycle.** Multiple PE platforms have built scaled home infusion and specialty pharmacy businesses, and most remain in active add-on mode. Strategic strategics (Option Care, CVS Coram, BrightSpring) also continue programmatic acquisition. **4. Fragmented mid-market.** Despite consolidation, hundreds of mid-sized regional home infusion and AIS businesses remain independent. The buyer-to-target ratio is favorable. --- ## Sub-Sector Valuation Ranges (Q2 2026) | Asset Type | EBITDA Size | Typical Multiple Range | |---|---|---| | Home infusion (multi-state platform) | $10M+ | 11x–14x | | Home infusion (regional) | $5M–$10M | 9x–12x | | Home infusion (single-state) | $2M–$5M | 7x–10x | | Home infusion (single pharmacy) | sub-$2M | 5x–8x | | AIS (ambulatory infusion suite) network | $5M+ | 10x–13x | | AIS (regional) | $2M–$5M | 8x–11x | | Specialty pharmacy (chronic therapy focused) | $5M+ | 9x–13x | | Specialty pharmacy (rare disease focused) | $5M+ | 10x–14x+ | | Hybrid home infusion + AIS platform | $5M+ | 10x–13x | Premiums apply for: rare-disease and biologic specialization, multi-state pharmacy licensure, accreditation breadth (URAC + ACHC), strong payer contract economics, low clinician turnover, and clean compliance histories. --- ## Payer Mix and Valuation Payer mix is a primary valuation driver in infusion M&A. ### Commercial Insurance (In-Network) - The dominant economic model for most home infusion and AIS platforms - Buyer focus: contract rates, S/T (specialty tier) status, network breadth, rate negotiation history - Premium multiples for diversified commercial mix with favorable rates ### Medicare Part B (Home Infusion Therapy Services Benefit) - Limited coverage relative to commercial; rate environment is challenging - Best as a complement to commercial business, not as primary economics ### Medicare Part D / Medicare Advantage - Specialty pharmacy economics primarily Part D - MA infusion benefit varies by plan - Plan contract diversity matters ### Medicaid and Medicaid Managed Care - State-by-state economics; some states favorable, many constrained - Valued as part of diversified mix; rarely as primary ### Manufacturer Direct Contracts (Limited Distribution Drugs / LDDs) - Limited Distribution Network (LDN) participation can be a meaningful value driver - Buyer underwriting heavily weighted to durability of LDN relationships - Manufacturer-mandated post-acquisition consents may apply --- ## Service Line Considerations ### Home Infusion (Per Diem + Drug Margin) - Traditional model: nursing visits + drug supply + supplies - Strong recurring revenue from chronic therapy patients - Buyer focus: drug acquisition cost discipline (340B if applicable, GPO efficiency), nursing utilization, gross-to-net economics - Therapy mix diversity (anti-infectives, TPN, immunoglobulins, biologics, hydration) drives durability ### Ambulatory Infusion Suite (AIS) - In-center infusion; lower clinical complexity, easier staffing - Payer site-of-care steerage favors AIS over hospital outpatient - Capex requirement and lease economics matter - Multi-suite networks command platform premium ### Specialty Pharmacy (Chronic and Rare Disease) - Distinct from infusion but often integrated - Patient management programs, adherence reporting, manufacturer reporting are key value drivers - LDN and limited distribution drug access is critical - Accreditation (URAC + ACHC + others) is foundational ### Compounding Pharmacy (503A + 503B) - Adjacent specialty - Higher regulatory intensity (FDA 503B, USP 797/800) - Different buyer pool --- ## The Most Active Infusion Buyers in 2026 ### Strategic Acquirers - **Option Care Health** (NASDAQ: OPCH) — largest home infusion strategic - **CVS Health / Coram Infusion** — major home infusion presence - **BrightSpring Health Services** (NASDAQ: BTSG) — home infusion through PharMerica / Amerita Specialty Infusion - **Soleo Health** — specialty infusion and pharmacy - **BioPlus Specialty Pharmacy** — specialty pharmacy and infusion - **Cardinal Health** — specialty pharmacy strategic activity - **McKesson-affiliated specialty platforms** - **InfuCare RX, Vital Care, KabaFusion** — regional and specialty platforms ### Most Active PE-Backed Platforms and Sponsors - **Madison Dearborn Partners** — historical home infusion activity - **Nautic Partners** — healthcare services portfolio - **Webster Equity Partners** — healthcare services - **Court Square Capital Partners** - **Linden Capital Partners** - **Audax Group** - **GTCR** - Multiple **independent sponsors** focused on specialty pharmacy and infusion The buyer pool for a quality home infusion or AIS platform is concentrated among 15–30 firms. Specialized advisor curation is essential. --- ## Diligence Items Unique to Infusion M&A Buyer diligence in infusion is highly technical. Expect deep scrutiny of: ### Pharmacy Operations and Compliance - USP 797 (sterile compounding) compliance - USP 800 (hazardous drug compounding) compliance - USP 825 (radiopharmaceutical compounding, where applicable) - State Board of Pharmacy licensure across all states served - DEA registration and controlled substance handling - FDA 503A or 503B status (for compounding) - Drug recall management protocols - Cold chain and supply chain integrity ### Accreditation - URAC Specialty Pharmacy, Home Infusion accreditation - ACHC Home Infusion accreditation - Joint Commission Home Care accreditation - Survey history for each accreditation - Re-accreditation timing relative to deal close ### Drug Economics - Drug acquisition cost analysis (340B participation if applicable, GPO contracts, wholesale) - Gross-to-net economics by therapy class - Manufacturer rebate and chargeback history - Specialty distributor relationships (AmerisourceBergen, Cardinal, McKesson) - Limited Distribution Drug (LDD) and Limited Distribution Network (LDN) participation ### Payer Contracts - In-network contract review by payer - Rate analysis vs. published benchmarks - Specialty tier (S/T) status - Contract auto-renewal and rate adjustment provisions - Authorization-to-billing efficiency - Recoupment and audit history ### Clinical Operations - RN, PharmD, and nurse practitioner licensure verification - Clinician turnover and retention - Patient management and adherence programs - Outcomes documentation - Adverse event reporting ### Regulatory - HIPAA compliance - FDA inspections and 483 history - DEA inspections and any administrative actions - State pharmacy board surveys --- ## Deal Structures Common in Infusion M&A ### Equity Rollover - Typical rollover for founder-led platforms: 15–35% - Reflects buyer desire for clinical continuity and growth alignment ### Earnout - Often used for emerging therapy areas or new geographic expansion - Tied to revenue, EBITDA, or therapy-class metrics ### Real Estate - AIS platforms with owned real estate often carve out into separate entity, lease back to buyer - Tax efficiency and ongoing income for the seller ### Working Capital - Particular focus on drug inventory valuation methodology - A/R aging by payer - Manufacturer rebate accruals --- ## Common Infusion Seller Mistakes **1. Single-buyer conversations.** The infusion buyer pool is concentrated but deep. Single-buyer conversations consistently leave value on the table. **2. Underestimating accreditation timing.** Buyers want fresh accreditation; expiring accreditation can cause deal delays. **3. Disorganized payer contract documentation.** In-network contracts are the central economic asset; disorganization costs price. **4. Inventory valuation surprises.** Drug inventory valuation methodology should be agreed at LOI, not the data room. **5. Underweighting LDN documentation.** Limited Distribution Network access is a strategic asset; document carefully. **6. Specialty pharmacy and infusion comingled financials.** Buyers value these differently; clean separation enables higher multiples. --- ## Preparing an Infusion Platform for Sale The 12–24 months before sale are when infusion platforms most successfully build value. **Operationally:** - USP 797/800 audit and remediation - Accreditation renewal timing aligned with sale process - Renegotiate key payer contracts where rates are below benchmark - Document LDN access and manufacturer relationships - Reduce clinician turnover; document retention initiatives - Diversify therapy mix and payer mix **Financially:** - Sell-side Quality of Earnings - Drug economics and gross-to-net analysis - Payer mix and rate analysis - Working capital benchmarking with inventory methodology **Legally:** - Pharmacy and DEA compliance audit - HIPAA and 42 CFR Part 2 review (if applicable) - Manufacturer contract assignment review - Payer contract change-of-control review --- ## How Hendon Partners Helps Infusion Sellers Hendon Partners advises owners of home infusion, AIS, and specialty pharmacy platforms through preparation, sale process, and close. Our buyer network includes the strategic acquirers and PE platforms most active in infusion M&A in 2026 — and our process design accommodates the technical complexity of pharmacy operations, payer contracts, and accreditation. **[Schedule a confidential infusion-focused conversation with Hendon Partners →](/contact-us)** --- *Hendon Partners is a sell-side only M&A advisory firm with infusion and specialty pharmacy transaction expertise. We advise owners of home infusion, ambulatory infusion suite (AIS), and specialty pharmacy platforms across the United States.* --- ## Frequently Asked Questions ### What are typical EBITDA multiples for home infusion businesses in 2026? Home infusion platforms with $5M+ EBITDA trade at 9x–13x. Smaller home infusion businesses with $2M–$5M EBITDA typically clear 7x–10x. Single-pharmacy operations clear 5x–8x. Specialty infusion focused on rare disease, biologics, or chronic therapy can earn premium multiples for clinical complexity and contract durability. ### Who buys home infusion and infusion pharmacy companies? The most active buyers are large home infusion strategics (Option Care Health, CVS Coram, BioPlus, Soleo Health, Amerita / PharMerica), specialty pharmacy strategics (BrightSpring, Cardinal Health, McKesson-affiliated), and PE-backed infusion platforms. Multiple PE platforms have built scaled home infusion businesses through aggressive add-on acquisition. ### What is driving infusion M&A activity in 2026? Three forces: (1) growing biologic and specialty drug pipeline shifting administration to home and AIS settings; (2) payer preference for lower-cost home infusion vs. hospital outpatient infusion; (3) PE platforms in active scale-up mode building national footprints. Demand fundamentals are durable and buyer competition is intense. ### What due diligence is unique to infusion pharmacy M&A? Infusion diligence focuses on USP 797/800 sterile compounding compliance, accreditation status (URAC, ACHC, JCAHO), state pharmacy licensure across all states served, DEA registration, payer contracts and rate analysis, drug acquisition cost (340B vs. GPO vs. wholesale) and gross-to-net economics, and clinician (RN, PharmD) retention and licensure. ### How does ambulatory infusion suite (AIS) economics differ from home infusion? AIS centers have higher fixed costs but greater clinical control, easier nursing labor, and growing payer preference for site-of-care steerage. Home infusion has lower fixed costs but higher per-visit nursing intensity. Hybrid platforms combining both models often achieve the best buyer reception and premium multiples.